N-(2-Chloro-6-methylphenyl)-N-4-pyridinylurea
CAS No. 97627-24-2
N-(2-Chloro-6-methylphenyl)-N-4-pyridinylurea( —— )
Catalog No. M26317 CAS No. 97627-24-2
N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea is an anticonvulsant agent, treatment of generalized tonic-clonic and partial seizures.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 53 | In Stock |
|
| 2MG | 29 | In Stock |
|
| 5MG | 48 | In Stock |
|
| 10MG | 82 | In Stock |
|
| 25MG | 164 | In Stock |
|
| 50MG | 259 | In Stock |
|
| 100MG | 416 | In Stock |
|
| 200MG | 576 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameN-(2-Chloro-6-methylphenyl)-N-4-pyridinylurea
-
NoteResearch use only, not for human use.
-
Brief DescriptionN-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea is an anticonvulsant agent, treatment of generalized tonic-clonic and partial seizures.
-
DescriptionN-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea is an anticonvulsant agent, treatment of generalized tonic-clonic and partial seizures.(In Vivo):N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea shows anticonvulsant activity at 30 mg/kg in the initial tests with no signs of ataxia until 300 mg/kg. The activity seen with 30 mg/kg 37 is still present 4 h postdose. Compound is effective against seizures induced by maximal electroshock but does not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that Compound would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures.
-
In Vitro——
-
In VivoCompound shows anticonvulsant activity at 30 mg/kg in the initial tests with no signs of ataxia until 300 mg/kg. The activity seen with 30 mg/kg 37 is still present 4 h postdose. Compound is effective against seizures induced by maximal electroshock but does not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that Compound would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound is selected for clinical trials.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptornAChR| PAFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number97627-24-2
-
Formula Weight261.71
-
Molecular FormulaC13H12ClN3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (477.63 mM)
-
SMILESCc1cccc(Cl)c1NC(=O)Nc1ccncc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Synthesis and anti-platelet activity of ferulamide derivativesJournal of Chinese Pharmaceutical Sciences, 2002, 54(1):41-52.
molnova catalog
related products
-
Obtustatin
Highly potent integrin α1β1 inhibitor (IC50 = 0.8 nM for α1β1 binding to type IV collagen). Selective for α1β1 over α2β1, αIIbβ3, αvβ3, α4β1, α5β6, α9β1 and α4β7. Inhibits FGF2-stimulated angiogenesis in the chicken chorioallantoic model. Displays antitumor efficacy in a synergistic mouse model of Lewis lung carcinoma; blocks human melanoma growth in nude mice.
-
MM0299
MM0299 is brain permeable, has anti-glioblastoma activity, inhibits lanosterol synthase (LSS), and induces EPC production in in situ GBM tumors.
-
Smurf1-IN-A01
Smurf1-IN-A01 is a ubiquitin ligase Smad ubiquitination regulatory factor-1 inhibitor (kd: 3.664 nM).
Cart
sales@molnova.com